CHM 5.56% 1.9¢ chimeric therapeutics limited

Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-21

  1. 760 Posts.
    lightbulb Created with Sketch. 524
    https://www.miragenews.com/car-t-cell-therapy-shows-promise-in-aggressive-1189756/
    https://www.nature.com/articles/s41591-024-02875-1?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news

    Results from another phase 1 study from the the city of hope and our very own Christine Brown.

    Looks like their response rate and overall survival rate was very similar to our early phase 1a data.

    I dare say when we find the dose sweet spot and start dosing patients in the 2nd line of treatment, as opposed to the later lines, we'll improve upon both response and survival.

    Important to remember also "Chlorotoxin in the hands of city of hope has bound to the glioblastomas of more patients and more cells within those patients than any other agent they've tried."
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
1.9¢
Change
0.001(5.56%)
Mkt cap ! $16.64M
Open High Low Value Volume
1.9¢ 1.9¢ 1.8¢ $18.60K 983.5K

Buyers (Bids)

No. Vol. Price($)
13 1522272 1.8¢
 

Sellers (Offers)

Price($) Vol. No.
1.9¢ 5000 1
View Market Depth
Last trade - 15.59pm 04/07/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.